These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 32343968)

  • 1. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
    Radbel J; Narayanan N; Bhatt PJ
    Chest; 2020 Jul; 158(1):e15-e19. PubMed ID: 32343968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
    Tholin B; Hauge MT; Aukrust P; Fehrle L; Tvedt TH
    J Med Case Rep; 2020 Oct; 14(1):187. PubMed ID: 33054818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia.
    Stephen S; Park YA; Chrysostomou A
    Nephrology (Carlton); 2020 Nov; 25(11):845-849. PubMed ID: 32776624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 and QT interval prolongation: more than just drug toxicity?
    Merino JL; Martínez-Cossiani M; Iniesta A; Escobar C; Rey JR; Castrejón-Castrejón S
    Europace; 2020 Oct; 22(10):1479. PubMed ID: 32441761
    [No Abstract]   [Full Text] [Related]  

  • 6. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
    Cai S; Sun W; Li M; Dong L
    Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three Cases of COVID-19 Disease With Colonic Manifestations.
    Sattar Y; Connerney M; Rauf H; Saini M; Ullah W; Mamtani S; Syed U; Luddington S; Walfish A
    Am J Gastroenterol; 2020 Jun; 115(6):948-950. PubMed ID: 32427677
    [No Abstract]   [Full Text] [Related]  

  • 8. Fatal SARS-CoV-2 infection in a renal transplant recipient.
    Dirim AB; Demir E; Ucar AR; Garayeva N; Safak S; Oto OA; Yazici H; Alibeyoglu AM; Orhun G; Cagatay AA; Turkmen A
    CEN Case Rep; 2020 Nov; 9(4):409-412. PubMed ID: 32564306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
    Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
    Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
    Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
    BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
    Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M
    Eur J Intern Med; 2020 Jun; 76():36-42. PubMed ID: 32448770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
    Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
    Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
    Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
    Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
    [No Abstract]   [Full Text] [Related]  

  • 17. A histopathological observation regarding the possibility of hemophagocytic lymphohistiocytosis in COVID-19 patients.
    Abdollahi A; Beigmohammadi MT; Safaei M; Mehrtash V; Jafarzadeh B
    J Gastrointestin Liver Dis; 2020 Sep; 29(3):475-476. PubMed ID: 32919429
    [No Abstract]   [Full Text] [Related]  

  • 18. Left ventricular dysfunction in COVID-19: A diagnostic issue.
    Jacquet-Lagrèze M; Riad Z; Hugon-Vallet E; Ferraris A; Fellahi JL
    Anaesth Crit Care Pain Med; 2020 Jun; 39(3):393-394. PubMed ID: 32562808
    [No Abstract]   [Full Text] [Related]  

  • 19. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine.
    Fontana F; Alfano G; Mori G; Amurri A; Tei L; Ballestri M; Leonelli M; Facchini F; Damiano F; Magistroni R; Cappelli G
    Am J Transplant; 2020 Jul; 20(7):1902-1906. PubMed ID: 32324331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.